Shelton Capital Management buys $5,133,407 stake in Biogen Inc (BIIB)

Biogen Inc (BIIB) : Shelton Capital Management scooped up 5 additional shares in Biogen Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 1, 2016. The investment management firm now holds a total of 15,975 shares of Biogen Inc which is valued at $5,133,407.Biogen Inc makes up approximately 0.45% of Shelton Capital Management’s portfolio.

Other Hedge Funds, Including , Aberdeen Asset Management Plcuk reduced its stake in BIIB by selling 2,700 shares or 2.6% in the most recent quarter. The Hedge Fund company now holds 101,091 shares of BIIB which is valued at $32,484,582. Biogen Inc makes up approx 0.12% of Aberdeen Asset Management Plcuk’s portfolio.Sit Investment Associates Inc reduced its stake in BIIB by selling 2,545 shares or 33.64% in the most recent quarter. The Hedge Fund company now holds 5,020 shares of BIIB which is valued at $1,455,449. Biogen Inc makes up approx 0.04% of Sit Investment Associates Inc’s portfolio.Tokio Marine Asset Management Co Ltd reduced its stake in BIIB by selling 242 shares or 0.99% in the most recent quarter. The Hedge Fund company now holds 24,198 shares of BIIB which is valued at $6,977,493. Biogen Inc makes up approx 0.70% of Tokio Marine Asset Management Co Ltd’s portfolio.Calamos Wealth Management reduced its stake in BIIB by selling 186 shares or 6.97% in the most recent quarter. The Hedge Fund company now holds 2,484 shares of BIIB which is valued at $716,261. Biogen Inc makes up approx 0.14% of Calamos Wealth Management’s portfolio.Creative Planning boosted its stake in BIIB in the latest quarter, The investment management firm added 5,545 additional shares and now holds a total of 37,468 shares of Biogen Inc which is valued at $9,411,587. Biogen Inc makes up approx 0.07% of Creative Planning’s portfolio.

Biogen Inc closed down -6.78 points or -2.11% at $314.56 with 20,02,341 shares getting traded on Thursday. Post opening the session at $320.15, the shares hit an intraday low of $314.01 and an intraday high of $320.45 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, Biogen Inc reported $5.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.52 according to the earnings call on Jul 21, 2016. Analyst had a consensus of $4.69. The company had revenue of $2894.00 million for the quarter, compared to analysts expectations of $2790.65 million. The company’s revenue was up 11.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.22 EPS.

Many Wall Street Analysts have commented on Biogen Inc. Biogen Inc was Initiated by Bernstein to “Outperform” on Jun 29, 2016. Biogen Inc was Downgraded by Citigroup to ” Neutral” on Jun 7, 2016.

Biogen Inc. formerly Biogen Idec Inc. is a global biopharmaceutical company. The Company is focused on discovering developing manufacturing and delivering therapies for neurological autoimmune and hematologic disorders. The Company develops manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Company’s marketed products include AVONEX PLEGRIDY TECFIDERA TYSABRI FAMPYRA for multiple sclerosis (MS) ALPROLIX for hemophilia B and ELOCTATE for hemophilia A among others. It also collaborates on the development and commercialization of RITUXAN (rituximab) which is a monoclonal antibody for the treatment of non-Hodgkin’s lymphoma chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is for the treatment of chronic lymphocytic leukemia.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *